Alcon (ALC) Q3 2026 earnings review
Alcon's eye-drop sales rise, but US rivals hurt surgical lenses
Alcon, the Swiss maker of contact lenses and eye-surgery gear, grew profit faster than sales as new eye drops and a customs refund offset shrinking cataract lens revenue. Third-quarter sales rose 5% to $2.7 billion, while profit per share excluding one-offs climbed 15% on factory savings, share buybacks and a $58 million tariff refund. Chief executive David J. Endicott said the group remains on track for its yearly goals despite rival pressure, and narrowed the full-year sales plan to about 6% growth.
| Net sales | $2,717M +5% from a year ago (+5% constant currency) |
|---|---|
| Implantable surgical lenses | $422M -2% from a year ago |
| Profit per share, excluding one-offs | $0.91 +15% from a year ago |
| Full-year profit-per-share outlook | Trimmed top +12% to +14% constant currency (was +12% to +15%) |
⚖️ Verdict: 🔴 Bearish
The story got worse because Alcon's most profitable surgical lenses shrank while the boost from its new surgery console began to fade. Sales of implantable lenses fell 2% as US surgeons tried competing lenses, and sales growth outside surgical machines slowed to about 4% by our math. The company also raised the cost of its restructuring plan to $230 million and shaved the top off its full-year margin and profit-per-share plans.
The question now is whether Alcon can keep sales growing at 6% or more next year once hospitals finish their first wave of Unity console upgrades. Optimists expect new dry-eye drops, the Neurotech retina deal and upcoming lens launches to pick up the slack, while sceptics see growth slipping toward 4% to 5%. Management's initial 2027 outlook in February will settle the debate.
🐂 Bull Case
New Eye Drops and Equipment Carry Growth
Alcon relies on a wave of new machines and eye drops to outgrow the broader eye-care market. In the third quarter, that product cycle kept working even as surgical equipment compared against the first quarter of last year's big console launch. Sales in ocular health, the unit that sells eye drops, rose 8% to $500 million, led by "our portfolio of dry eye products, including Tryptyr and Systane".
- Surgical equipment and other sales: $269 million, up 11% from a year ago
- Surgical consumables (single-use packs for operations): $789 million, up 6%
- Contact lenses: $737 million, up 4% reported and 5% in constant currency
Equipment growth slowed from 26% in the second quarter because Alcon is now comparing against last autumn's rollout of Unity, its new cataract and retina surgery console, and Valeda, a light-therapy device for dry macular degeneration. Still, double-digit growth on top of last year's 13% jump shows hospitals are still buying the machines. Every console installed also locks in years of single-use consumable sales.
What to watch: fourth-quarter equipment sales against last year's $277 million peak. Holding positive growth against that high bar would prove that new additions like the Unity M surgical microscope can keep equipment revenue from rolling over in 2027.
Tariff Refunds and Factory Savings Lifted Margins
Profit margins rose in the third quarter because Alcon collected a large customs refund and ran its factories more efficiently. Operating margin excluding one-offs climbed 1.6 percentage points from a year ago to 21.8%, while reported operating margin rose 1.2 points to 14.0%. The company credited "tariff refunds of $58 million, lower amortization and manufacturing efficiencies" for the improvement.
Cost of net sales — the cost of making Alcon's lenses, drops and machines — fell by 3.5 percentage points of sales to 40.4%. Selling, general and administrative expenses (sales and overhead costs) moved the other way, rising 0.8 points of sales to 34.2% because the Swiss group spent most of the customs windfall on marketing. "Approximately two-thirds of the refund benefit is being reinvested in the business," the company wrote.
By our math, stripping out the net customs benefit of about $19 million leaves operating margin excluding one-offs near 21.0%, still almost a full point above last year. Vision Care carried that underlying gain, with its segment profit margin jumping 3.8 points to 25.8% on higher prices and better factory output.
What to watch: fourth-quarter operating margin excluding one-offs, which the full-year plan puts near 21.0% by our math. Reaching that level without another tariff refund will show how much of the margin gain comes from lasting factory savings.
Buybacks and Neurotech Deal Put Cash to Work
Alcon is using its cash flow to shrink its share count and buy new eye treatments after walking away from two earlier takeover deals. In the third quarter, the eye-care group spent $210 million buying back its own shares, bringing nine-month repurchases to $574 million and cutting diluted shares by 2.5% from a year ago to 483.3 million. That lower share count turned a 12% rise in profit excluding one-offs into 15% growth per share.
In October, the company also closed the purchase of Neurotech Pharmaceuticals for $550 million in upfront cash plus future sales milestones. Neurotech is a biotech firm "developing innovative cell therapies for chronic and neurodegenerative eye diseases", and brings Encelto, an approved treatment for a rare retinal condition called MacTel. In October, Alcon also won US regulatory approval for Brytly, an over-the-counter redness-reliever eye drop.
What to watch: fourth-quarter disclosure on Neurotech's initial sales contribution and research expenses. That will show whether the $550 million purchase adds to earnings next year or requires heavy upfront spending first.
🐻 Bear Case
US Rivals Push Implantable Lens Sales Down
"We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas of competitive pressure," chief executive David J. Endicott said. That pressure sits inside Alcon's high-margin surgical implantables unit, which sells artificial lenses placed inside the eye during cataract surgery (intraocular lenses, or IOLs) and tiny implants for glaucoma.
After growing between 2% and 4% for four straight quarters, implantables revenue fell 2% from a year ago to $422 million in the third quarter. The company said intraocular lens sales dropped 1% in constant currency because of "competitive pressures in the U.S.", while lower sales of surgical glaucoma devices pulled the category down another point. International growth and demand for PanOptix Pro, Alcon's newest multifocal lens, were not enough to offset the US losses.
The drop matters because artificial lenses carry some of Alcon's highest profit margins. In the third quarter, Surgical segment profit margin rose only 0.6 percentage points even with tariff refunds, as the company noted that unfavourable product mix held profits back. When surgeons switch to rival lenses in the United States, Alcon loses its most profitable surgical revenue stream.
What to watch: fourth-quarter implantables revenue and updates on the rollout of Vivity Pro, Alcon's next extended-depth-of-focus lens. A second quarter of shrinking lens sales would show that PanOptix Pro alone cannot stop US market-share losses.
Equipment Slowdown Pulls Total Growth Down to 5%
Alcon's long-term goal calls for 6% to 8% yearly sales growth in constant currency, built on an eye-care market growing 3% to 4% plus 2 percentage points from new products. In the third quarter, total sales growth slowed to 5% (4.9% reported) from 8% in the second quarter, and the company lowered its full-year assumption for overall market growth from a 3%–4% range to about 3%.
During the first half of 2026, a 26% jump in surgical equipment masked slower growth across the rest of the business. Now that the Unity console has passed its one-year launch anniversary, equipment growth cooled to 11% in the third quarter. By our math, Alcon's sales outside surgical equipment grew just 4.4% from a year ago, down from 6.3% in the second quarter and 8.0% in the first.
Because the rest of the portfolio is growing below 5% and the broader market is only growing about 3%, Alcon's full-year outlook of roughly 6% constant-currency growth leans heavily on its first-half lead. By our math, the full-year plan points to reported sales growth of about 5.4% in the fourth quarter.
What to watch: management's initial 2027 sales outlook when fourth-quarter results arrive in February. A target below 6% would confirm that growth slows down once the initial wave of Unity machine orders passes.
Restructuring Costs Rise while Profit Outlook Narrows
In February 2026, Alcon launched a restructuring plan to streamline operations, originally estimating $150 million in total costs to generate $100 million in yearly savings. In November, the company expanded the programme, raising the expected cost by $80 million to about $230 million while lifting the yearly savings target by $30 million to about $130 million. Alcon recorded $36 million of restructuring charges in the third quarter, bringing nine-month costs to $157 million.
The company said it will use the extra $30 million in savings to "help offset inflationary pressures" rather than to lift profits. At the same time, Alcon trimmed the top end of its full-year constant-currency margin expansion plan from 1.9 percentage points to 1.5 points, and cut the top of its core earnings-per-share growth plan from 15% to 14%. Spending more on restructuring while lowering the profit ceiling suggests rising operating costs are eating up the savings.
What to watch: fourth-quarter restructuring charges and whether the programme finishes on schedule at year-end. Any spillover of charges into 2027 would mean the overhaul is taking longer and costing more than planned.
👓 Other Themes
New US Tariffs Replace Struck-Down Import Duties
After the US Supreme Court struck down earlier emergency import duties in February, Alcon recovered $59 million of the $64 million it had paid, including interest. However, when temporary replacement duties expired in July, the US government imposed new Section 301 tariffs of 10% to 12.5% on imports from 86 countries. Even with those new duties, the refund allowed Alcon to narrow its expected full-year net tariff cost to about $40 million, down from $40–90 million in August.
💲 Other KPIs
Free cash flow — operating cash flow minus factory equipment purchases — rose 8% over the first nine months to $1,345 million. By our math, third-quarter free cash flow jumped 16% from a year ago to $652 million, or 24% of net sales, helped by higher customer collections, lower staff bonus payouts, and the $59 million customs refund.
Both working-capital lines grew faster than third-quarter sales (+4.9%). Inventories rose 5.6% from a year ago to $2,569 million to stock up for new product launches, while trade receivables — money owed by customers — climbed 7.3% to $2,048 million as sales outpaced cash collections, tying up $291 million of working capital over nine months.
Net debt — total debt of $4,767 million minus $1,827 million in cash and short-term investments — fell by $185 million since December and by 9.0% from a year ago. In September, the eye-care maker issued 500 million euros ($568 million) of 3.875% notes due in 2033 to pay off $500 million of maturing 2026 notes, leaving 98% of its debt at fixed rates.
🔮 Guidance
Unchanged at the middle of the range. Alcon narrowed its full-year constant-currency sales plan from 5%–7% to about 6%, with currency adding another 0.9 percentage points to reported growth. After 7% reported growth in the first nine months, the full-year target leaves about 5.4% reported growth for the fourth quarter by our math, as surgical equipment compares against last year's strong launch quarter.
Trimmed at the middle of the range. The Swiss group raised the floor of its constant-currency margin expansion plan by 0.1 percentage points but cut the ceiling by 0.4 points, lowering the middle of the range from +1.4 points to +1.25 points (plus 0.1 points from currency). By our math, that puts full-year margin excluding one-offs at 21.15% and fourth-quarter margin near 21.0%, down from 21.8% in the third quarter.
Trimmed at the top end. After raising its constant-currency profit-per-share outlook twice this year (+1.0 point in May, +2.0 points in August), Alcon shaved 1 point off the top of the range, lowering the middle by 0.5 points to 13.0% (14.6% reported including a 1.6-point currency boost). By our math, that implies fourth-quarter profit per share excluding one-offs of about $0.92, up 18% from last year's weak fourth quarter.
Raised by $10 million. This line covers net interest costs, currency hedging losses, and losses from minority-owned companies; it had stood at $200–220 million since February. Through nine months, net non-operating expenses were $162 million, as lower interest income on cash and higher foreign-exchange losses reduced financial income.
Slightly lower. Management widened the tax rate plan to 19%–20% from about 20% previously, putting the middle of the range 0.5 percentage points lower at 19.5%. The tax rate excluding one-offs was 17.8% in the third quarter and 19.4% over the first nine months.
Lowered by 1 million shares. Following $210 million of third-quarter buybacks, Alcon reduced its full-year share-count estimate from 488 million (and 498 million at the start of the year). Because the nine-month average is already 487.4 million and the third quarter stood at 483.3 million, full-year shares should finish near 486 million.
❓ Key Questions
What was premium cataract lens adoption in the third quarter?
Alcon did not publish its quarterly estimate for advanced-technology intraocular lens adoption in the release. Investors need to know whether surgeons slowed their upgrades to premium lenses, or whether rival lenses took a larger piece of a growing market.
How much did US lens losses vs glaucoma hurt implantables?
Implantables revenue fell 2% as intraocular lenses shrank 1% in constant currency and surgical glaucoma devices declined. Quantifying the split between US cataract lens share losses and glaucoma weakness will show how urgently Alcon needs Vivity Pro to defend its core business.
Why did efficiency costs jump $80 million for $30 million in savings?
The expanded restructuring programme costs an extra $80 million for $30 million of additional yearly savings, a much worse return than the original $150 million for $100 million plan. Management has not explained which new projects or severance actions drove the cost increase.
What will Neurotech and Encelto do to 2027 margins?
Alcon paid $550 million at closing in October for Neurotech and its approved MacTel cell therapy, Encelto. Without Neurotech's current revenue or research budget, investors cannot tell whether the deal adds to or reduces next year's profit per share.